Efficacy and Safety of Fecal Microbiota Transfer (FMT) for Recurrent Urinary Tract Infections in Women

Inclusion Criteria:

Women ≥18 years of age with UTIs (≥3 episodes in one year or ≥2 in six months) who meet at least one of the following criteria

* UTIs despite having used other prophylactic strategies.
* HUTI due to resistant bacteria (ESBL- or carbapenemase-producing Enterobacteriaceae, and quinolone-resistant Pseudomonas aeruginosa or Enterococcus faecium).
* Allergy or previous adverse reactions to available oral antibiotics (usually beta-lactams, but could occur with other antibiotic families) for prophylaxis and/or treatment.

Exclusion Criteria:

* Have symptoms compatible with symptomatic UTI at the time of inclusion or be undergoing treatment for it.
* Be receiving another preventive strategy for UTIs at the time of study inclusion: prophylactic antibiotics, bladder instillation with hyaluronic acid, D-mannose, or therapeutic vaccines. In the case of the latter, Version 3.0\_ March 22, 2023 13 patients who have received them must have had at least two recurrences despite their administration.
* Rifaximin allergy.
* Inability to understand the study and sign the informed consent form, and to collect stool and urine samples.
* Pregnancy or breastfeeding
* Patients with bone marrow or solid organ transplants (patients who have been transplanted for ≥ 5 years and are stable from a transplant perspective are allowed to be included).
* Any clinically significant disease at the investigator's discretion, other than UTIs, that is not medically controlled at the time of study inclusion.
* Patients with lithiasis or permanent catheters (patients with self-catheters are excluded).